SG11201503051QA - Formulations of pyrimidinedione derivative compounds - Google Patents

Formulations of pyrimidinedione derivative compounds

Info

Publication number
SG11201503051QA
SG11201503051QA SG11201503051QA SG11201503051QA SG11201503051QA SG 11201503051Q A SG11201503051Q A SG 11201503051QA SG 11201503051Q A SG11201503051Q A SG 11201503051QA SG 11201503051Q A SG11201503051Q A SG 11201503051QA SG 11201503051Q A SG11201503051Q A SG 11201503051QA
Authority
SG
Singapore
Prior art keywords
formulations
derivative compounds
pyrimidinedione derivative
pyrimidinedione
compounds
Prior art date
Application number
SG11201503051QA
Other languages
English (en)
Inventor
Yanxia Li
Ping Gao
Yi Shi
Hao Hou
Michael Mackaplow
Kelley A Meadows
Geoff G Zhang
Yi Gao
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of SG11201503051QA publication Critical patent/SG11201503051QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201503051QA 2012-10-18 2013-10-18 Formulations of pyrimidinedione derivative compounds SG11201503051QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261715766P 2012-10-18 2012-10-18
PCT/US2013/065760 WO2014063101A1 (en) 2012-10-18 2013-10-18 Formulations of pyrimidinedione derivative compounds

Publications (1)

Publication Number Publication Date
SG11201503051QA true SG11201503051QA (en) 2015-05-28

Family

ID=49554481

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201503051QA SG11201503051QA (en) 2012-10-18 2013-10-18 Formulations of pyrimidinedione derivative compounds

Country Status (11)

Country Link
US (2) US9629841B2 (https=)
EP (1) EP2908808A1 (https=)
JP (2) JP6266635B2 (https=)
CN (2) CN104853752B (https=)
AU (1) AU2013330993B2 (https=)
BR (1) BR112015008927A2 (https=)
CA (1) CA2888883A1 (https=)
EA (2) EA028481B1 (https=)
MX (1) MX2015004973A (https=)
SG (1) SG11201503051QA (https=)
WO (1) WO2014063101A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
BR112022017758A2 (pt) * 2020-03-05 2022-11-29 Aurigene Discovery Tech Ltd Composições farmacêuticas de um inibidor de quinase

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4442257A1 (de) * 1994-11-28 1996-05-30 Beate Dr Podschun Sparsomycin
DE69934582T2 (de) 1998-06-11 2007-10-04 Pharmacia & Upjohn Co. Llc, Kalamazoo Delavirdin tablettenformulierung
CN1402629A (zh) 1999-12-23 2003-03-12 辉瑞产品公司 提供提高的药物浓度的药物组合物
GB0009522D0 (en) * 2000-04-19 2000-06-07 Smithkline Beecham Plc Composition
US6489363B2 (en) * 2000-10-11 2002-12-03 Cephalon, Inc. Pharmaceutical solutions of modafinil compounds
CA2590675A1 (en) * 2004-12-15 2006-06-22 Elan Pharma International Ltd. Nanoparticulate tacrolimus formulations
WO2007044574A2 (en) * 2005-10-06 2007-04-19 Transtech Pharma, Inc. Pharmaceutical compositions, methods of preparation thereof, and methods of treatment
PA8796201A1 (es) 2007-09-17 2009-04-23 Abbott Lab Agentes anti-infecciosos y su uso
PL2639226T3 (pl) * 2007-09-17 2017-02-28 Abbvie Bahamas Ltd. Pirymidyny o działaniu przeciw zakaźnym oraz ich zastosowania
US20100166861A1 (en) * 2008-12-29 2010-07-01 Kelly Noel Lynch Pharmaceutical formulations of sevalamer, or salts thereof, and copovidone
US20130109707A1 (en) * 2010-03-01 2013-05-02 Concert Pharmaceuticals ,Inc. Fluorouracil derivatives
DE202012012955U1 (de) * 2011-10-21 2014-07-14 Abbvie Inc. Eine Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen (DAAs) für die Verwendung zur Behandlung von HCV

Also Published As

Publication number Publication date
CA2888883A1 (en) 2014-04-24
MX2015004973A (es) 2015-07-17
EA201590752A1 (ru) 2016-02-29
BR112015008927A2 (pt) 2017-07-04
EP2908808A1 (en) 2015-08-26
JP2018065858A (ja) 2018-04-26
US9629841B2 (en) 2017-04-25
EA028481B1 (ru) 2017-11-30
US10201542B2 (en) 2019-02-12
US20170181973A1 (en) 2017-06-29
CN109260207A (zh) 2019-01-25
EA201791354A2 (ru) 2017-11-30
US20140113921A1 (en) 2014-04-24
JP6266635B2 (ja) 2018-01-24
JP2015534985A (ja) 2015-12-07
EA032913B1 (ru) 2019-08-30
WO2014063101A1 (en) 2014-04-24
CN104853752A (zh) 2015-08-19
AU2013330993B2 (en) 2018-03-01
AU2013330993A1 (en) 2015-05-07
EA201791354A3 (ru) 2018-03-30
CN104853752B (zh) 2018-10-23

Similar Documents

Publication Publication Date Title
IL277652A (en) Stable aqueous formulations of adlimumab
ZA201501847B (en) Formulations of enzalutamide
PT2827862T (pt) Formulações de bendamustina
SG11201405958RA (en) Nicotine formulation
PL4082524T3 (pl) Preparaty triazynowe
ZA201500290B (en) Crystalline forms of dihydropyrimidine derivatives
SG11201503051QA (en) Formulations of pyrimidinedione derivative compounds
ZA201502350B (en) Solid form of hihydro-pyrido-oxazine derivative
HUE036665T2 (hu) Dihidro-pirido-oxazin származék szilárd formái
IL234771B (en) Nicotine formulation
GB201206178D0 (en) Formulations